| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 67.69M | 23.8M | 55.29M | 61.28M | 32.71M | 29.05M |
| Revenue Growth % | - | -0.65% | 1.32% | 0.11% | -0.47% | -0.11% |
| Cost of Goods Sold | 1.13M | 2.06M | 8.97M | 13.13M | 1.6M | 911K |
| COGS % of Revenue | 0.02% | 0.09% | 0.16% | 0.21% | 0.05% | 0.03% |
| Gross Profit | 66.56M | 21.74M | 46.32M | 48.15M | 31.11M | 28.14M |
| Gross Margin % | 0.98% | 0.91% | 0.84% | 0.79% | 0.95% | 0.97% |
| Gross Profit Growth % | - | -0.67% | 1.13% | 0.04% | -0.35% | -0.1% |
| Operating Expenses | 598.98M | 1.09B | 1.4B | 1.22B | -4.47B | 1.03B |
| OpEx % of Revenue | 8.85% | 45.92% | 25.29% | 19.97% | -136.52% | 35.5% |
| Selling, General & Admin | 335.77M | 259.88M | 775.03M | 600.51M | 416.13M | 591.41M |
| SG&A % of Revenue | 4.96% | 10.92% | 14.02% | 9.8% | 12.72% | 20.36% |
| Research & Development | 263.22M | 236.63M | 483.04M | 525.22M | 439.91M | 550.41M |
| R&D % of Revenue | 3.89% | 9.94% | 8.74% | 8.57% | 13.45% | 18.95% |
| Other Operating Expenses | 0 | 596.13M | 139.89M | 97.75M | -5.32B | -110.39M |
| Operating Income | -532.42M | -1.07B | -1.35B | -1.18B | 4.5B | -1B |
| Operating Margin % | -7.87% | -45.01% | -24.45% | -19.18% | 137.47% | -34.53% |
| Operating Income Growth % | - | -1.01% | -0.26% | 0.13% | 4.83% | -1.22% |
| EBITDA | -553.3M | -895.74M | -1.35B | -1.16B | 4.52B | -989.22M |
| EBITDA Margin % | -8.17% | -37.64% | -24.34% | -18.87% | 138.14% | -34.05% |
| EBITDA Growth % | - | -0.62% | -0.5% | 0.14% | 4.91% | -1.22% |
| D&A (Non-Cash Add-back) | -20.88M | 175.16M | 5.93M | 18.86M | 22.04M | 14.07M |
| EBIT | -553.3M | -895.74M | -916.71M | -1.2B | -824.93M | -1.11B |
| Net Interest Income | 10.31M | -1.39M | -6.67M | 4.22M | 111.65M | 258.38M |
| Interest Income | 17.99M | 1.42M | 369K | 32.18M | 146.43M | 258.38M |
| Interest Expense | 7.68M | 2.81M | 7.04M | 27.97M | 34.78M | 0 |
| Other Income/Expense | -28.56M | 172.35M | 427.89M | -49.52M | 70.82M | 321.7M |
| Pretax Income | -560.99M | -898.55M | -923.75M | -1.22B | 4.57B | -681.59M |
| Pretax Margin % | -8.29% | -37.76% | -16.71% | -19.99% | 139.63% | -23.46% |
| Income Tax | 7.12M | 1.69M | 369K | 5.19M | 21.5M | 48.17M |
| Effective Tax Rate % | -2.14% | 0.9% | 0.92% | 0.82% | 0.95% | 0.25% |
| Net Income | 1.2B | -809.23M | -845.26M | -1.01B | 4.35B | -171.98M |
| Net Margin % | 17.74% | -34.01% | -15.29% | -16.47% | 132.94% | -5.92% |
| Net Income Growth % | - | -1.67% | -0.04% | -0.19% | 5.31% | -1.04% |
| Net Income (Continuing) | -568.11M | -900.23M | -924.12M | -1.23B | 4.55B | -729.76M |
| Discontinued Operations | 1.72B | 0 | 0 | 114.56M | -315.15M | 373.03M |
| Minority Interest | 76.53M | 264.22M | 404.49M | 449.82M | 479.95M | 499.59M |
| EPS (Diluted) | 1.75 | -1.18 | -1.26 | -1.42 | 5.23 | -0.24 |
| EPS Growth % | - | -1.67% | -0.07% | -0.13% | 4.68% | -1.05% |
| EPS (Basic) | 1.75 | -1.18 | -1.26 | -1.42 | 5.55 | -0.24 |
| Diluted Shares Outstanding | 684.79M | 684.79M | 669.75M | 712.79M | 831.05M | 725.4M |
| Basic Shares Outstanding | 684.79M | 684.79M | 669.75M | 712.79M | 783.25M | 725.4M |
| Dividend Payout Ratio | - | - | - | - | 0% | - |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 2.22B | 2.19B | 2.15B | 1.8B | 6.73B | 5B |
| Cash & Short-Term Investments | 2.19B | 2.13B | 2.06B | 1.68B | 6.54B | 4.89B |
| Cash Only | 2.19B | 2.13B | 2.06B | 1.68B | 6.54B | 2.72B |
| Short-Term Investments | 0 | 0 | 0 | 5.01M | 5.37M | 2.17B |
| Accounts Receivable | 15.28M | 13.83M | 6.73M | 37.64M | 82.81M | 0 |
| Days Sales Outstanding | 82.39 | 212.17 | 44.44 | 224.22 | 924 | - |
| Inventory | 0 | 0 | 0 | 2.76M | 35.25M | 0 |
| Days Inventory Outstanding | - | - | - | 76.76 | 8.05K | - |
| Other Current Assets | 2.14M | 874K | 26.02M | 20.44M | 17.59M | 113.17M |
| Total Non-Current Assets | 257.81M | 502.7M | 438.61M | 591.02M | 490.65M | 436.88M |
| Property, Plant & Equipment | 73.93M | 77.03M | 86.95M | 92.34M | 65.95M | 101.08M |
| Fixed Asset Turnover | 0.92x | 0.31x | 0.64x | 0.66x | 0.50x | 0.29x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 144.88M | 137.84M | 0 |
| Long-Term Investments | 177.22M | 398.47M | 325.83M | 304.32M | 247.75M | 302.94M |
| Other Non-Current Assets | 6.66M | 27.2M | 25.82M | 49.48M | 39.11M | 32.86M |
| Total Assets | 2.48B | 2.69B | 2.59B | 2.39B | 7.22B | 5.44B |
| Asset Turnover | 0.03x | 0.01x | 0.02x | 0.03x | 0.00x | 0.01x |
| Asset Growth % | - | 0.09% | -0.04% | -0.08% | 2.02% | -0.25% |
| Total Current Liabilities | 92.12M | 218.96M | 184.37M | 272.45M | 266.76M | 149.41M |
| Accounts Payable | 10.31M | 20.55M | 34.58M | 37.83M | 53.23M | 23.69M |
| Days Payables Outstanding | 3.33K | 3.65K | 1.41K | 1.05K | 12.15K | 9.49K |
| Short-Term Debt | 7.84M | 12.31M | 0 | 40.72M | 12M | 9.84M |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 39.74M | 141.42M | 83.98M | 74.84M | 85.94M | 53.93M |
| Current Ratio | 24.09x | 9.99x | 11.64x | 6.60x | 25.24x | 33.47x |
| Quick Ratio | 24.09x | 9.99x | 11.64x | 6.59x | 25.10x | 33.47x |
| Cash Conversion Cycle | - | - | - | -750.81 | -3.18K | - |
| Total Non-Current Liabilities | 276.24M | 308.73M | 339.33M | 509.57M | 507.19M | 100.33M |
| Long-Term Debt | 108.59M | 170.28M | 210.03M | 375.51M | 430.59M | 0 |
| Capital Lease Obligations | 64.45M | 62.38M | 62.47M | 53.48M | 47.27M | 90.33M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 103.19M | 76.06M | 53.09M | 80.58M | 29.34M | 10M |
| Total Liabilities | 368.36M | 527.69M | 523.7M | 782.02M | 773.95M | 249.74M |
| Total Debt | 180.88M | 244.98M | 283.89M | 481.4M | 499.75M | 100.17M |
| Net Debt | -2B | -1.89B | -1.78B | -1.2B | -6.04B | -2.62B |
| Debt / Equity | 0.09x | 0.11x | 0.14x | 0.30x | 0.08x | 0.02x |
| Debt / EBITDA | - | - | - | - | 0.11x | - |
| Net Debt / EBITDA | - | - | - | - | -1.34x | - |
| Interest Coverage | -69.30x | -381.24x | -191.97x | -42.02x | 129.31x | - |
| Total Equity | 2.11B | 2.16B | 2.06B | 1.61B | 6.45B | 5.19B |
| Equity Growth % | - | 0.03% | -0.05% | -0.22% | 3.01% | -0.2% |
| Book Value per Share | 3.08 | 3.16 | 3.08 | 2.26 | 7.76 | 7.15 |
| Total Shareholders' Equity | 2.03B | 1.9B | 1.66B | 1.16B | 5.97B | 4.69B |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -1.11B | -1.92B | -2.76B | -3.77B | 576.17M | 116.06M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.35M | 1.45M | -946K | -2.62M | -4.08M | 9.44M |
| Minority Interest | 76.53M | 264.22M | 404.49M | 449.82M | 479.95M | 499.59M |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -761.83M | -552.14M | -677.73M | -843.39M | -765.27M | -839.45M |
| Operating CF Margin % | -11.25% | -23.2% | -12.26% | -13.76% | -23.39% | -28.89% |
| Operating CF Growth % | - | 0.28% | -0.23% | -0.24% | 0.09% | -0.1% |
| Net Income | -519.39M | -900.23M | -924.12M | -1.12B | 4.23B | -356.73M |
| Depreciation & Amortization | 0 | 0 | 5.93M | 18.86M | 22.04M | 14.07M |
| Stock-Based Compensation | 0 | 84.96M | 564.96M | 217.78M | 199.63M | 289.03M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -257.73M | 191.2M | -340.22M | 29.09M | -5.24B | -708.77M |
| Working Capital Changes | 15.3M | 71.94M | 15.72M | 6.34M | 19.04M | -77.05M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 6.6M | 3.75M | 15.4M | 4.36M | 22.68M | -18.17M |
| Cash from Investing | 1.69B | -31.7M | 303.3M | -44.27M | 5.2B | -1.77B |
| Capital Expenditures | -4.92M | -5.81M | -17.44M | -12.69M | -1.38M | -4.6M |
| CapEx % of Revenue | 0.07% | 0.24% | 0.32% | 0.21% | 0.04% | 0.16% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -20.05M | -25.9M | 600K | -139.43M | 5.24B | 110.47M |
| Cash from Financing | 217.16M | 456.26M | 306.79M | 499.46M | 419.36M | -1.22B |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | -6M | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 83.48M | 508K | 291.98M | -10M | 17.51M | 13.41M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -766.75M | -557.94M | -695.16M | -856.08M | -766.65M | -844.05M |
| FCF Margin % | -11.33% | -23.45% | -12.57% | -13.97% | -23.44% | -29.05% |
| FCF Growth % | - | 0.27% | -0.25% | -0.23% | 0.1% | -0.1% |
| FCF per Share | -1.12 | -0.81 | -1.04 | -1.20 | -0.92 | -1.16 |
| FCF Conversion (FCF/Net Income) | -0.63x | 0.68x | 0.80x | 0.84x | -0.18x | 4.88x |
| Interest Paid | 0 | 2.02M | 5.54M | 5.3M | 10.27M | 5.96M |
| Taxes Paid | 0 | 4.08M | 916K | 5.13M | 12.35M | 61.91M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 56.93% | -37.9% | -40.03% | -55% | 107.97% | -2.96% |
| Return on Invested Capital (ROIC) | -383.61% | -424.59% | -362.59% | -252.9% | 817.89% | -50.42% |
| Gross Margin | 98.33% | 91.36% | 83.78% | 78.58% | 95.11% | 96.86% |
| Net Margin | 1773.57% | -3400.86% | -1528.89% | -1646.59% | 13294.18% | -591.96% |
| Debt / Equity | 0.09x | 0.11x | 0.14x | 0.30x | 0.08x | 0.02x |
| Interest Coverage | -69.30x | -381.24x | -191.97x | -42.02x | 129.31x | - |
| FCF Conversion | -0.63x | 0.68x | 0.80x | 0.84x | -0.18x | 4.88x |
| Revenue Growth | - | -64.85% | 132.34% | 10.84% | -46.62% | -11.19% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Product | 28.01M | 75.06M | 75.06M |
| Product Growth | - | 167.96% | 0.00% |
Roivant Sciences Ltd. (ROIV) reported $20.3M in revenue for fiscal year 2024. This represents a 70% decrease from $67.7M in 2019.
Roivant Sciences Ltd. (ROIV) saw revenue decline by 11.2% over the past year.
Roivant Sciences Ltd. (ROIV) reported a net loss of $374.0M for fiscal year 2024.
Roivant Sciences Ltd. (ROIV) has a return on equity (ROE) of -3.0%. Negative ROE indicates the company is unprofitable.
Roivant Sciences Ltd. (ROIV) had negative free cash flow of $784.4M in fiscal year 2024, likely due to heavy capital investments.